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ABSTRACT: Previous studies have identified a CCAAT/enhancer binding protein (C/EBP) site located downstream of the transcriptional start
site (DS3). The role of the DS3 element with respect to HIV-1 transactivation by Tat and viral replication has not been characterized. We have
demonstrated that DS3 was a functional C/EBPβ binding site and mutation of this site to the C/EBP knockout DS3-9C variant showed lower HIV-1
long terminal repeat (LTR) transactivation by C/EBPβ. However, it was able to exhibit similar or even higher transcription levels by Tat compared
to the parental LTR. C/EBPβ and Tat together further enhanced the transcription level of the parental LAI-LTR and DS3-9C LTR, with higher levels
in the DS3-9C LTR. HIV molecular clone viruses carrying the DS3-9C variant LTR demonstrated a decreased replication capacity and delayed
rate of replication. These results suggest that DS3 plays a role in virus transcriptional initiation and provides new insight into C/EBP regulation of
HIV-1.
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Introduction

Human immunodeficiency virus type 1 (HIV-1) gene expression in cells of the monocyte–macrophage lineage has been
shown to be critically dependent on the regulation of the long
terminal repeat (LTR), the promoter that drives proviral gene
expression from the integrated viral DNA template. In turn,
LTR activation requires cellular transcription factors, such as
nuclear factor-κB (NF-κB), CCAAT/enhancer binding protein (C/EBP), Sp1, and activating transcription factor/cyclic
AMP response element binding protein (ATF/CREB), and a
number of other transcription factors as previously reviewed.1–3
Four C/EBP binding sites have been identified within the
HIV-1 subtype B LTR, three located upstream of the HIV-1
LTR transcriptional start site (C/EBP US1, US2, US3),4 and
one located downstream of the transcriptional start site (C/
EBP-DS3).5 A number of studies have characterized the functional properties of the two upstream C/EBP binding sites, C/
EBP US1 and US2, which are required for HIV-1 replication
in cells of the monocyte–macrophage lineage but not for replication in T-cells.6,7 Additionally, specific sequence configurations of C/EBP US1 have been shown to correlate with the
development of HIV-1-associated dementia (HAD) and
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disease progression.8–10 The C/EBP family has been shown to
be composed of at least six different proteins (C/EBP-α, β, γ,
δ, ε, and ζ) and belongs to the basic leucine zipper transcription
factor family.11 C/EBPβ has been reported to regulate HIV-1
transcription in different cell types in association with a number of cellular factors including Sp1, NF-κB, ATF/CREB, and
CBP/p300 and the viral proteins, such as Tat and Vpr.8,12–21
The HIV-1 Tat protein is an 81-101 amino acid protein
that has been shown to be necessary for HIV-1 replication and
transcription as previously reviewed.22–25 Tat has been shown
to mediate transactivation of HIV-1 through binding to the
Tat-activated region at the 5′ end of all HIV-1 mRNAs. The
interaction of Tat with Tat-activated region results in the
recruitment of positive transcriptional elongation factor
(p-TEF), composed of cyclin-dependent kinase 9 (cdk9), and
its partner, cyclin T1.26,27 p-TEF is responsible for phosphorylation of the C-terminal domain of RNA polymerase II
(RNA Pol II) and promotes transcription elongation.28,29 Tat
was able to regulate the activity of HIV-1 LTR by interacting
with a number of proteins, including Sp1, NF-κB, C/EBPβ,
and CBP/p300.30–35 Specifically, Tat directly binds to C/EBPβ
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in vitro and in vivo through amino acid residues 47–67.36
Furthermore, Tat expression in HeLa cells has been shown to
lead to a significant increase in the nuclear levels of C/EBPβ
and a corresponding increase in C/EBPβ DNA-binding activity to the IL-6 promoter.36 More recently, co-expression of Tat
and C/EBPβ has been shown to enhance C/EBPβ binding to
the HIV-1 LTR19 and modulate monocyte chemoattractant
protein 1 (MCP-1) gene transcription in astrocytes.37 Based
on the critical role of MCP-1 in monocytic infiltration to the
site of injury or inflammation in the brain38–40 and the ability
of C/EBPβ to stimulate the basal and Tat-mediated MCP-1
transcription, it has been proposed that the interaction
between Tat and C/EBPβ may be important in HIV-1 infection, especially in the development of HAD.37
Recent studies have shown that the C/EBP-DS3 was able
to regulate HIV-1 basal transcription level in U-937 cells, and
the HIV-1 LTR containing a DS3 knockout phenotype
(DS3-9C) exhibited a reduced level of HIV-1 basal transcription.5 Other transcription factor binding sites identified
downstream of the HIV-1 transcriptional start sites, including binding sites for AP-1 (I, II, III), AP3-like (AP3-L), and
Sp1, have been shown to regulate HIV-1 transcription and
replication.41–44 Given the importance of the upstream C/
EBP binding sites in HIV-1 replication in cells of the monocyte–macrophage lineage, the function of this newly identified downstream C/EBP binding site (C/EBP-DS3) was
examined in this study. The studies reported herein indicate
that the downstream C/EBP binding site was a functional C/
EBP binding site. Transactivation of the HIV-1 LTR by C/
EBPβ was inhibited when the LTR contained the DS3-9C
variant. When C/EBPβ and Tat were expressed at increased
concentrations, the response of the LTR depended on the
concentration of each protein. If there were limited Tat and
increasing levels of C/EBPβ, then loss of binding to DS3 due
to the 9C variant demonstrated a decreased ability to transactivate the LTR. However, when C/EBPβ was limited with
increasing amounts of Tat, the loss of binding at DS3 due to
the 9C variation demonstrated an increased ability to transactivate the LTR. HIV-1 replication in U-937 monocytic cells
showed a delay in replication at early time points most likely
due to low levels of C/EBPβ and Tat and recovery of virus
replication toward levels generated by the parental virus at
later time points when there would be increased levels of Tat.
Overall, DS3 plays a critical role in initiating HIV-1 subtype
B transcription and replication.

Materials and methods
Cell culture and cell treatments
The U-937 human monocytic cell line (American Type Culture
Collection. ATCC, CRL-1593.2) was grown in Roswell Park
Memorial Institute medium (RPMI)-1640 media (Cellgro).
Media was supplemented with 10% heat-inactivated fetal
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bovine serum (FBS; Hyclone), antibiotics, (penicillin,
100 U/mL, and streptomycin, 100 µg/mL; Cellgro), glucose
(4.5 g/L, Cellgro), sodium pyruvate (1 mM, Cellgro), and
HEPES (10 mM, Cellgro). 293T cells were maintained in
Dulbecco’s Modified Eagle Medium (ATCC) supplemented
with FBS (10%), glucose solution (10%), sodium bicarbonate
(2%), and antibiotics (penicillin and streptomycin at 40 µg/mL
each). The cells were maintained at 37°C with 5% CO2.

Cloning and site-directed mutagenesis
The LTR-containing DNA fragment (approximately 640 bp)
was derived from the LAI molecular clone of HIV-1. The
HIV-1 LAI-LTR was PCR amplified using the forward primer:
5′-GGGGTACCTGGAAGGGCTAATTCACTCC-3′ and
reverse primer: 5′-TCCCCCGGGTG TAGAGATTTT
CCACA-3′ (Integrated DNA Technologies). The italicized
nucleotides indicate the restriction endonuclease binding sites
used for cloning. The amplified product was digested with KpnI
and Sma I (Promega, Madison, WI) and ligated into a modified
pGL3-Basic vector, which contains the firefly luciferase (Luc)
gene (Promega), to construct the parental LAI-LTR-Luc
expression construct. The parental construct was used as a template for site-directed mutagenesis using the QuikChange
mutagenesis procedure as described by the manufacturer
(Stratagene) to construct the mutant construct LAI-DS3-9CLuc. The following primers were used for site-directed
mutagenesis, and the nucleotide that was mutated is underlined
TAGTCAGTGTGCAAAATCTCTAGC (Integrated DNA
Technologies). The LAI-DS3-9C-Luc has been shown to contain the DS3 element with a G-to-C bp change at position 9 of
the binding site of the subtype B consensus sequence (a sequence
alteration specifically shown to completely abrogate C/EBPβ
binding).5 All plasmids used in these studies were sequenced to
verify the sequence configurations. Sequences were analyzed
using Lasergene software (DNASTAR, Inc.).
The C/EBPβ-2 expression construct was generated by PCR
amplification from human C/EBPβ cDNA (Open Biosystems,
Human Verified Full-length cDNA Clones, MHS 1011) utilizing forward primer: 5′-CACCATGGAAGTGGCCAA
CTTCTACTA-3′ and the reverse primer: 5′-CTAGCAGTGG
CCGGAGGAGGCGAG-3′ (Integrated DNA Technologies,
Coralville, IA). The italicized nucleotides in the forward primers correspond to sequence necessary for directional cloning
into the pcDNA3.1 TOPO vector (Invitrogen), while the
underlined portion corresponds to the respective start site of
translation. The amplified C/EBPβ PCR product was ligated
into the pcDNA3.1 TOPO vector as described by the manufacturer (Invitrogen). The plasmid was verified by sequencing.
To confirm proper protein expression, 30 µg of the C/EBPβ
construct was transiently transfected into 3.0 × 107 293 F cells
using 293fectin as described by the manufacturer (Invitrogen),
and the cell nuclear extract was harvested for further analyses

Liu et al
48 hours posttransfection. Western immunoblot analysis was
performed with the nuclear extract using antibody specific for
C/EBPβ (C/EBPβ, sc-150, Santa Cruz Biotechnology Inc.)
for detection of a 45-kD protein. Electrophoretic mobility shift
supershift analyses were performed to identify the specific proteins involved in DNA–protein complex formation (data not
shown).

Transient transfection analyses
Exponentially growing U-937 cells were seeded at 1 × 106 cells
in 2 mL of growth medium in 6-well plates on the day of
transfection. Fugene6 transfection reagent was utilized in the
transient transfection as described by the manufacturer
(Rocher). Briefly, 1 µg LAI-LTR-luciferase (LAI-LTR-Luc
reporter construct or LAI-LTR containing the DS3-9C
variant (LTR-DS3-9C-Luc) and 50 ng pRL-TK Renilla
luciferase internal control (Promega) were transfected together
or cotransfected with other expression vectors: pcDNA3.1C/EBPβ-2 and/or pcDNA3-Tat86. pcDNA3.1-C/EBPβ-2 is
described above. pcDNA3-Tat86 expression vector was provided by Dr. Kamel Khalili (Temple University, Philadelphia,
PA). The pcDNA3.1 vector without an insert was used to give
each transfection an equal amount of total DNA. Cells were
harvested 24 hours posttransfection, and cell lysates were prepared using 50 µL 1× passive lysis buffer (Promega). Luciferase
activity was assayed using the dual luciferase assay system as
described by the manufacturer (Promega). Normalization to
an internal control plasmid was not performed in the experiments with cotransfection expression vectors because previous
studies and our results have demonstrated the responsiveness
of widely used internal control vectors to cotransfected transcriptional regulators.45–48 Each value represents the average of
triplicate transfection reactions and is representative of at least
three independent experiments. The error bars shown in each
figure indicate the standard deviation.

Molecular clones and infection experiment
An infectious molecular clone corresponding to the LAI
strain of HIV-1 (pLAI.2) was obtained as a glycerol stock
from the NIH AIDS Research and Reference Reagent
Program (Catalog number 2532, NIH, MD). Escherichia coli
containing the molecular clone were grown in Luria-broth
(MILLER) supplemented with ampicillin (100 mg/mL) at
30°C, 200 RPM overnight. DNA was isolated using an
EndoFree Maxiprep procedure as described by the manufacturer (USB). The 3′ LTR was digested from the molecular
clone using AatII and BamHI (NEBiolabs) and ligated into
pUC19 (NEBiolabs). The LTR was subjected to site-directed
mutagenesis to incorporate 9C mutations into C/EBP-DS3.
Mutagenesis primers were the same as utilized in site-directed
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mutagenesis for constructing LAI-LTR-DS3-9C-Luc
described above. The mutated LTR was digested from
pUC19 and ligated back into the parental molecular clone.
The parental and mutant molecular clones were sequenced
completely to confirm the presence of DS3 mutant and the
absence of any other mutations in the HIV-1 genome subsequent to the mutagenesis process.
Molecular clone DNA (10 µg) was transfected into 293T
cells in 10 cm dishes using the ProFection mammalian transfection system (E1200; Promega). Forty-eight hours after
transfection, cell supernatants were collected and assayed for
p24 using Enzyme-linked immunosorbent assay (ELISA) as
directed by the manufacturer (Perkin Elmer). U-937 cells
were seeded at a density of 6 × 104 cells/well in a 96-well
v-bottom plate. Cells were then incubated for two hours with
25 ng/mL p24 of molecular clone-derived HIV-1 LAI
parental or LAI 9C strains complexed with Transfectam
(Promega). Virus–Transfectam complexes were prepared by
mixing 25 ng/mL p24 of virus with 5 mg/mL of Transfectam
in a total of 0.5 mL of serum-free RPMI. After incubating at
37°C for 45 minutes, the medium volume was increased to
3 mL with RPMI containing antibiotics and FBS to bring
the serum concentration to 10%. Following the two-hour
incubation with virus, cells were washed and subsequently
cultured. The supernatant was collected, and the cells were
washed, supplied with new media, and split at 3-day intervals
for a total of 12 days. The supernatant from days 3, 6, 9, and
12 was subsequently assayed for HIV-1 production by determining the level of p24 core antigen in the supernatant using
an HIV-1 p24 antigen ELISA assay (ZeptoMetrix Corp.).
Infectivity was expressed relative to mock-infected cells.

Statistical analysis
The results were statistically analyzed by Student’s t-test.
Differences between groups were considered significant if P <
0.05 was obtained.

Results
C/EBP-DS3 affects HIV-1 LTR transcription
activated by C/EBPβ in U-937 cells
Although U-937 cells represent a promonocytic cell line,
undifferentiated U-937 cells are exclusively susceptible to
infection by CXCR4-utilizing (X4) HIV-1 strains and have
been utilized in a number of HIV-1 replication studies to
examine selected aspects of the viral life cycle.49 In particular,
U-937 cells and X4 HIV-1 strains have been previously utilized for identifying upstream C/EBP binding sites required
for HIV-1 replication in cells of the monocyte–macrophage
lineage.6,7 Moreover, electrophoretic mobility shift analyses
have shown that HIV-1 C/EBP-DS3 is able to form a
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Figure 1. DS3-9C exhibited reduced ability to be transactivated by C/EBPβ. U-937 cells were transiently transfected with 1 µg LAI-LTR-Luc or LAI-DS39C-Luc in the absence or presence of increasing amounts of C/EBPβ, as indicated in the figures. Twenty-four hours posttransfection, cell lysates were
harvested and luciferase activity was measured. (A) Results were analyzed by comparing the fold over the parental basal LTR activity level. (B) Results
were analyzed by comparing the fold over its own basal LTR activity level. Asterisk indiscates that P value < 0.001. (C) The protein expression levels of
C/EBPβ as demonstrated by Western blot were increased with the increasing amounts of C/EBPβ expression vectors cotransfected with LAI-LTR-Luc
(upper) or LTR-DS3-9C-Luc (lower) in U-937 cells.

DNA–protein complex containing C/EBPβ protein from
U-937 cell nuclear extract.5 Therefore, the role of C/EBPDS3 in HIV-1 transcription was first investigated in U-937
promonocytic cells.
U-937 promonocytic cells were transfected with 1 µg
parental HIV-1 LAI-LTR-Luc or the LAI-DS3-9C-Luc in
the absence or presence of increasing amounts of C/EBPβ-2
(activator) expression plasmid (Figure 1). Western immunoblot assays were performed to demonstrate that the protein
expression levels of C/EBPβ were increased in a dosedependent manner when cotransfected with parental LTR or
LTR-DS3-9C (Figure 1C). Expression of increasing amounts
of C/EBPβ-2 (from 150, 300, 600 to 1200 ng per reaction)
led to a dose-dependent increase in HIV-1 LTR activity in
both the parental and DS3-9C LTR, with the parental
LTR demonstrating a 2- to 5-fold higher level of activity
(Figure 1). Specifically, in the presence of 1200 ng of C/EBPβ
expression vector, when comparing to fold over the parental
LTR basal activity, the maximal transactivation levels of
parental LTR and LTR-DS3-9C were 5.5- and 1.9-fold,
respectively (Figure 1A). When the results were analyzed as
fold over their own basal activity, the transactivation levels
were 5.5- and 3.3-fold, respectively (Figure 1B). These results
indicated that, similar to the upstream C/EBP binding sites,
C/EBP-DS3 was able to affect HIV-1 transcription through
interaction with C/EBPβ. Specifically, the reduced occupancy
of DS3 resulted in reduced ability to be transactivated by
C/EBPβ.

Tat activates the LTR-DS3-9C variant in U-937
monocytic cells
Previous studies have shown that some transcription factor
binding sites located downstream of the HIV-1 transcriptional
start site play an important role in the Tat-mediated transactivation of the HIV-1 LTR.41,50 To determine whether C/
EBP-DS3 could also affect Tat transactivation of the LTR,
U-937 cells were transfected with 1 µg parental LAI-LTR-Luc
or LTR-DS3-9C-Luc reporter vectors in the absence or presence of increasing amounts of Tat. As shown in Figure 2, Tat
expression increased the activity of both the parental and DS39C-containing LTRs. In the presence of 50 ng of Tat expression vector, the activity of the HIV-1 LTR was similar between
the parental and DS3-9C-containing configurations, with
elevated activities of 13.8- and 14.2-fold, respectively. In the
presence of increasing amounts of Tat expression vectors from
150, 300 to 600 ng, both LTRs exhibited increased activity in a
dose-dependent manner. Specifically, the parental LTR transactivation levels were increased up to 20-, 29.6-, and 35.7-fold,
respectively, which was higher than the levels of LTR-DS3-9C,
16.7-, 19.7-, and 24.7-fold, respectively (Figure 2A). However,
when 1200 ng Tat expression vector was added to the cells, the
transactivation level of LTR-DS3-9C (38.9-fold) was similar
to that of parental level (36.4-fold). These results indicated
that the LTR-DS3-9C variant needed much higher concentrations of Tat to be activated to levels similar to parental LTRs
when there were low levels of C/EBPβ present (similar to
those detected in U-937 cells). When analyzing the results
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Figure 2. DS3-9C impacts Tat transactivation of the HIV-1 LTR. U-937
cells were transiently transfected with 1 µg LAI-LTR-Luc or LAI-DS3-9CLuc in the absence or presence of increasing amounts of Tat expression
vectors as indicated. Cell lysates were collected and processed for
luciferase activity 24 hours posttransfection. (A) Fold over parental basal
activity. (B) Fold over their own basal activity. Asterisk indicates that P
value < 0.05.

obtained with the parental and LTR-DS3-9C variant by comparing each LTR to its own basal transcription level, increasing
Tat expression increased the transcription levels of DS3-9Ccontaining LTRs by 26.0-, 31.9-, 38.0-, 47.5-, and 74.3-fold,
respectively, which were actually higher than the levels of the
parental LTR, 13.8-, 20.0-, 29.6-, 35.7-, and 36.4-fold, respectively (Figure 2B). These results suggest that Tat can help overcome the loss of C/EBP-mediated LTR activation, at least
under selected physiological conditions.

HIV-1 LTR activities are further elevated by
C/EBPβ and Tat together
Since the LTR-DS3-9C variant exhibited a lower transactivation capability in the presence of C/EBPβ while achieving
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normal or even a higher level in the presence of Tat, and both
factors have been shown to be important for HIV-1 gene
expression in cells of monocyte–macrophage lineage, further
investigations to determine whether there was a specific interaction between C/EBPβ, Tat, and the HIV-1 LTR-DS3 variant were performed. U-937 cells were transfected with 1 µg
parental or LTR-DS3-9C in the absence or presence of 50 ng
Tat expression vector and increasing amounts of C/EBPβ
expression vector. As shown in Figure 3, the cooperative interaction between Tat and C/EBPβ-2 has been observed in both
LTR configurations. In particular, when analyzed as fold over
the parental basal LTR activity level (Figure 3A), increasing
amounts of C/EBPβ-2 (100–1200 ng) increased the parental
LTR from 26-, 26.3-, 43.0- to 41.3-fold, respectively, while the
LTR activity of the LTR-DS3-9C variant were increased by
16.8-, 33.2-, 30.6-, and 16.0-fold, respectively. Unlike the
parental LTR, with greater amounts of C/EBPβ-2 (600 and
1200 ng), the transcription level of LTR-DS3-9C was
decreased. When analyzed as fold was over their own basal
transcription activity (Figure 3B), the maximal transcription
level of LTR-DS3-9C-driven transcription was obtained with
50 ng Tat and 300 ng C/EBPβ-2 (55.9-fold), which was higher
than the highest level achieved with the parental LTR (43.0fold). These results indicated that the LTR-DS3-9C variant
exhibited a greater ability to be induced by Tat and C/EBPβ-2
together, once LTR-DS3-9C basal level was enhanced to the
level of the parental LTR.
In contrast, when U-937 cells were transfected with 1 µg
parental LAI-LTR-Luc or LAI-DS3-9C-Luc in the absence
or presence of 100 ng C/EBPβ expression vector and a series of
increasing amounts of Tat expression vectors, LTR activity was
increased in both parental and DS3-9C-containing LTRs. The
maximum activity of the parental LTR and the LTR-DS3-9C
variant occurred with 100 ng C/EBPβ and 600 ng Tat expression vector, 37.7- and 50.2-fold, respectively. In addition, in all
Tat levels examined, LTRs containing the DS3-9C configuration resulted in increased LTR activity over the parental LTR
demonstrating that loss of C/EBP binding to DS3 can be
overcome by increased expression of C/EBPβ (which can be
found in the cells of the activated monocyte–macrophage lineage) and increased expression of Tat, leading one to conclude
that DS3-9C may be involved in controlling HIV-1 replication
in activated monocyte–macrophage environments.

DS3-9C decreases HIV-1 LAI replication in
U-937 monocytic cells
To determine the effects of DS3 on HIV-1 replication, the
DS3-9C variation was incorporated into an infectious molecular clone of the LAI strain of HIV-1. Molecular clone-derived
viral particles were used to infect U-937 cell lines (Figure 4).
Levels of p24 in the media were measured at 3, 6, 9, and 12
days postinfection. In U-937 cells, when compared with the
parental LAI viral strain, the HIV-1 DS3-9C-containing
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Figure 3. Tat and C/EBPβ were able to cooperatively increase HIV-1 parental LTR and LTR-DS3-9C. (A) and (B) U-937 cells were transiently transfected
with 1 µg LAI-LTR-Luc or LTR-DS3-9C-Luc in the absence or presence of 50 ng Tat and increasing amounts of C/EBPβ (100, 300, 600, to 1200 ng)
together. (C) and (D) U-937 cells were transiently transfected with 1 µg LAI-LTR-Luc or LAI-DS3-9C-Luc in the absence or presence of 100 ng C/EBPβ
and increasing amounts of Tat (100, 300, 600, to 1200 ng) together. Twenty-four hours posttransfection, cell lysates were collected and luciferase activity
was measured. The results shown in (A) and (C) indicate the fold over parental LTR basal activity, and the results shown in (B) and (D) indicate the fold
over their own basal transcription level.

LAI strain, a CXCR4-utilizing virus, was examined in this
study, it was able to effectively infect U-937 cells, which has
also been demonstrated in other studies.51,52 Therefore, the
comparison of the replication levels of these two viruses indicated that the DS3-9C variant exhibited a decreased replication ability at early time points but clearly has the ability to
reach parental levels at later time points.

Discussion

Figure 4. HIV-1 LAI molecular clones containing DS3-9C demonstrated
an altered replication phenotype. Molecular clone-derived viral particles
were used to infect U-937 monocytic cells as described in the “Materials
and methods” section. Levels of p24 in the media were measured at 3, 6,
9, and 12 days postinfection. The gray line corresponds to the HIV-1 LAI
parental virus. The black line corresponds to the LAI virus containing the
DS3-9C variant configuration.

variant viruses resulted in lower replication levels at each time
point examined. However, the maximal p24 level of parental
virus was 213 ng/mL at 3 days postinfection, after which time
lower levels of virus were observed. However, the replication
levels of HIV-1 DS3-9C variant viruses continuously increased
from day 3 (p24 level was 53 ng/mL) to day 12 (p24 level was
112 ng/mL) postinfection (Figure 4). Although the HIV-1

Although numerous studies have investigated the important
roles played by upstream cis-acting transcription factor binding
sites and their cognate transcription factors regulating HIV-1
gene expression, relatively few studies have been reported concerning the transcription factor binding sites located downstream of the transcriptional start site of HIV-1 LTR. The
sequence analyses have shown that some transcription factor
binding sites located downstream of the transcriptional start
site exhibit a high degree of sequence conservation by comparison to the subtype B consensus sequence.5 High sequence conservation may indicate the positive selection of these sites
during the course of viral evolution within patients and across
the infected patient population. For example, the downstream
AP-1 binding sites within subtype B LTRs have been shown to
be highly conserved genotypically5 and affect the basal and
Tat transactivation ability of the HIV-1 LTR.42,50 Proviruses
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containing mutations in three AP-1 binding sites abolished
HIV-1 replication in peripheral blood mononuclear cells and
T-lymphocyte cell lines.41 Therefore, to better understand the
pathogenesis of HIV-1, a more thorough characterization of
the HIV-1 LTR is required, including studies of the transcription factor binding sites located downstream of the transcriptional start site.
Cells of the monocyte–macrophage lineage are important
for HIV-1 replication and long-term persistence of HIV-1.
Unlike T-lymphocytes, cells of the monocyte–macrophage lineage infected with HIV-1 are resistant to the cytopathic effects
of the virus and serve as a long-lived reservoir for HIV-1persistent infection.49,53 Furthermore, the ability of macrophages to migrate into other tissues or to invade the brain is
relative to a number of HIV-1-associated diseases, including
HAD.54 Additionally, studies have shown that cells of monocytic origin are able to harbor latent HIV-1 provirus in all
stages of the disease even in patients receiving successful highly
active antiretroviral therapy, indicating that in addition to resting CD4+ T-cells, monocyte–macrophage are another potential latent virus reservoir, which may be able to continue to
accumulate and harbor replication-competent HIV-1.55–58
Results reported herein suggest that one downstream C/EBP
site with low DNA binding affinity for C/EBPβ (DS3-9C)
might be related to HIV-1 persistence and reactivation in cells
of the monocyte–macrophage lineage.
HIV-1 LTRs containing the DS3-9C configuration (a
knockout configuration) exhibit relatively lower basal5 and C/
EBPβ-mediated LTR activity (Figure 1), suggesting that
DS3-9C could function as a negative regulatory element, to
suppress HIV-1 transcription, especially at the beginning of
infection when minimal viral protein has been produced yet,
helping HIV-1 to evade the immune response by essentially
increasing the energy of activation required to achieve the productive virus replication phase driven by high concentrations of
Tat. However, once the infected cells are activated by proper
extracellular stimuli or in the presence of enough Tat protein,
LTR-DS3-9C could function at levels comparable to parental
LTRs or even with higher LTR activity (Figures 2 and 3).
Specifically, compared with parental LTR, although the activity levels of LTR-DS3-9C were lower at certain quantities of
Tat (150, 300, and 600 ng), LTR-DS3-9C was able to be activated to the similar levels in the presence of 50 and 1200 ng
Tat, respectively, indicating that (1) LTR-DS3-9C was able to
respond rapidly to the low quantities of Tat, which could be
important for HIV-1 transcription initiation, and (2) LTRDS3-9C was able to act as transcription-competent LTR in
the presence of large quantities of Tat. The results also suggested that once LTR-DS3-9C activation was initiated, which
was approximated in the assays by analyzing the results as fold
over their own basal level, the maximal activity level of LTRDS3-9C activation by Tat (74.3-fold) was significantly higher
than that of parental LTR (36.6-fold), suggesting that (3)
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Figure 5. Three possible outcomes of HIV-1 infection in T-lymphocytes
and cells of the monocyte–macrophage lineage. Left: productive HIV-1
infection without immunologic control; middle: productive infection with
immunologic control; right: low productive infection with immune evasion.
Since the infected cells are activated, the expression of cellular factors
(NF-κB, Sp1, and C/EBPβ) are increased and/or enough amounts of Tat
are available, these viruses are able to be transcription and replication
competent.

LTR-DS3-9C exhibited a greater degree of Tat inducibility.
Additionally, when the LTR-DS3-9C was activated by the
small amounts of C/EBPβ, LTR-DS3-9C exhibited a higher
level of transactivation in the presence of Tat (Figure 3C and
D), which further confirmed LTR-DS3-9C as a transcriptioncompetent variant. The replication results demonstrated that
although the levels of DS3-9C variant viruses were lower than
those of the parental virus during the first 12 days postinfection, the levels were continuously increased while those of
parental viruses attained a maximal level at 3 days postinfection
and then started to decline (Figure 4), suggesting that there
may be a delay in virus replication. Taken together, these results
suggest that this site is regulated by the cell activation state and
produced viral proteins, especially, the amounts of C/EBPβ
and Tat present within the infected cell.
HIV-1 infection in T-lymphocytes or cells of the monocyte–macrophages could result in three possible outcomes: (1)
productive replication without efficient immune recognition
leading to extensive viral production and the death of the host
cells; (2) productive replication with immune recognition leading to the clearance of infected cells prior to high-level virus
production; and (3) infection leading to limited viral gene
expression and failure to eliminate infected cells by the immune
system with continued maintenance of latent or persistent provirus within the infected cell population (Figure 5). Based on
these observations, we propose that infection with virus containing the LTR-DS3-9C variant could lead to the third outcome. Specifically, during the early stage of HIV-1-DS3-9C
infection, no Tat protein was produced and the transcription
was totally dependent on host cell factors (NF-κB, Sp1,
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C/EBPβ, CBP/p300, PCAF, etc.).17,59–62 LTR-DS3-9Ccontaining viruses exhibited relatively low basal transcription
and replication level, which helped DS3-9C viruses evade
immune system surveillance and perhaps be retained in the
infected cell population. With disease progression and/or some
external stimuli, the infected cells were activated; the active
form of NF-κB could be produced and translocated to the
nucleus; and the expression levels of Sp1 and C/EBPβ were
increased, all promoting HIV-1 transcription initiation.
Subsequently, Tat was produced, and efficient transcription
elongation occurred, allowing DS3-9C variant viruses to replicate with a delayed phenotype.
Recent studies have shown the linkage between HIV-1 replication and disease progression with genetic alterations in
selected transcription factor binding sites within the HIV-1
LTR, such as Sp1-binding sites63,64 and US1 C/EBP site.10 It
is possible that virus containing the DS3-9C variant might be
associated with a greater propensity to establish latency.
Defective HIV-1 transcription, which could be caused by (1)
low levels of NF-κB,65–67 (2) low levels of Tat,68–72 and (3) limited cellular coactivators, such as cyclin T1, a component of the
p-TEF complex,65,73 is one of the major reasons for HIV-1
latency. Although transient transfection provides a simpler
chromatin structure, it helps in understanding activities of integrated LTRs. The establishment of an open nuc-1 is critical for
HIV-1 gene expression74,75 and DS3-9C is located at the 3′
edge of nucleosome-1 (nuc-1), so it is possible that DS3-9C
variant may lead to a structural change in the LTR that results
in a specific restrictive chromatin structure limiting the accessibility of Tat and coactivators (HAT and/or SWI/SNF) to the
LTR, thereby resulting in a low level of HIV-1 transcription
and possibly latency. Within the context of proper stimuli, the
latent viruses are able to reactivate and function as parental
viruses.

Conclusion

The function of one C/EBP binding site located downstream
of the HIV-1 LTR transcription start site has been characterized. This binding site configuration with low DNA binding affinities for C/EBPβ (DS3-9C) may be transcriptionally
competent and be able to facilitate productive replication in
the presence of Tat. This LTR variant may promote HIV-1
persistence and reactivation in cells of the monocyte–macrophage lineage. Further experiments will examine the role
of this interesting cis-acting element in vivo, utilizing stably
integrated LTRs or genomes containing the DS3-9C variant
in different cell types under an assortment of stimulatory
conditions. With respect to the important roles played by
upstream and downstream C/EBP binding sites in the regulation of HIV-1 gene expression in cells of the monocyte–
macrophage lineage, C/EBP binding sites may be the
potential targets for design of novel forms of HIV-1
therapeutics.
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